Follow-on roundup: Sage, Foamix

Sage Therapeutics Inc. (NASDAQ:SAGE) and Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) raised a combined $180 million in follow-on offerings on Wednesday.

Sage raised $120 million through the sale of 2.3 million shares at $52.50 in a deal underwritten by JPMorgan; Goldman Sachs; Leerink; and Cowen. Sage proposed the offering on Monday when its shares closed at $52.25. The stock gained $5.81 (11%) to $59.50 on Wednesday. Sage hopes to begin a Phase III trial in mid-2015 of lead compound SAGE-547, a positive allosteric modulator (PAM) of GABA A receptor to treat super-refractory status epilepticus (SRSE). ...